1. Introduction {#sec0005}
===============

Cancer is a leading cause of death worldwide representing about one-eighth of all deaths (<http://www.who.int/mediacentre/factsheets/fs297/en/>) and being strongly affected by demographic changes especially ageing of the population. In 2008, more than 12.7 million people were newly diagnosed with cancer accounting for 7.6 million deaths, with over one quarter of the global cancer incidences occurring in Europe. Furthermore, cancer has also emerged as a major public health problem in developing countries. According to the World Health Organization new cases of cancer impairment will strongly increase with estimated death rates of up to 11 million in the year 2030. Although in recent decades much progress has been achieved in respect of therapies, like surgery, chemotherapy, radiation or hormone ablation therapy, they are not successful in more than 50% of cases ([http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900](http://globocan.iarc.fr/factsheets/populations/factsheet.asp%3Funo=900)). Furthermore, for those who survive the risk of reoccurrence of the disease is a major problem. If the tumor progresses or reoccurs, chemotherapy is the standard treatment. However, resistance as well as potential toxicity and the many side effects of chemotherapeutics, which are mainly due to inadequate specificity for tumor cells, represent a major limitation in this type of therapy. Hence, increasingly the identification of more specific targets generally expressed within a certain tumor type is a major issue in anticancer research. While considerable attention is paid to receptors of growth factors and proteins involved in cell--cell signaling relatively little effort has been devoted to targeting cancer cell membranes *per se*. Thus, this review will focus on a promising new approach in cancer therapy which is based on host defense peptides -- effector molecules of innate immunity that specifically target cancer cells and destroy them within minutes, mostly by damaging cell membrane without binding to specific receptors.

2. Deficits and drawbacks of conventional cancer therapies -- need for novel treatment strategies {#sec0010}
=================================================================================================

Before development of chemotherapeutics in the 1940s ([@bib0730]), surgical removal of tumor tissue was the only available treatment and can still often be successfully applied for localized cancers for which radiation therapy is also widely used to target cells by directly damaging DNA ([@bib0805]). Nevertheless, many cancer types advance rapidly, reoccur or tend to metastasize making chemotherapy the treatment of choice ([@bib0220]). Currently used anticancer drugs are mostly based on alkylating agents, antimetabolites as well as natural products and derivatives thereof. Between 1940 and 2006, 175 new anticancer drugs were approved ([@bib0525]). More than 50% thereof are biological (10% are usually large peptides and proteins), natural (14%) or naturally derived products (28% are semisynthetic modifications) ([Fig. 1](#fig0005){ref-type="fig"}). Early compounds were based on nitrogen mustards, a powerful class of agents that alkylate bases of DNA ([@bib0735]), leading to cell death. A second class of chemotherapeutics, the antimetabolites, such as aminopterin and amethopterin, do not directly interact with DNA bases but interfere with synthesis of precursors as folate and cause mistakes during DNA replication of cancer cells ([@bib0730]). In the 1960s, natural-product anticancer drugs started to be developed such as e.g. Vinca alkaloids that inhibit microtubule polymerization and thereby cell division or antracyclines that promote cell death upon intercalation in DNA and inhibition of replication ([@bib0100; @bib0075]). In the decades that followed a large number of further chemotherapeutics such as taxol or halychondrines and E7389 were developed that interfere with a variety of biological targets ([@bib0325]).

2.1. Side effects owing to insufficient selectivity {#sec0015}
---------------------------------------------------

Most conventional chemotherapeutics, however, exhibit insufficient selectivity against healthy mammalian cells causing deleterious side effects ([@bib0750; @bib0085; @bib0340]). Commonly, these agents act on cells that divide rapidly, one of the main properties of cancer cells. Therefore, damage can be expected in particular in rapidly dividing normal cells, like bone marrow, gastrointestinal mucosa and hair follicles, resulting in the most common side effects of chemotherapy like myelosuppression (decreased production of blood cells), mucositis (inflammation of the lining of the digestive tract) and alopecia (hair loss). Newer chemotherapies, such as the use of monoclonal antibodies ([@bib0500]), immunotoxins ([@bib0575]) or angiogenesis inhibitors ([@bib0480]), target specific differences between tumors and healthy cells and tissues, thereby exhibiting lower toxicity. However, side effects have also been observed.

2.2. Formation of resistance {#sec0020}
----------------------------

Besides toxicity, resistance to treatment with anticancer drugs is a huge problem. Resistance can be intrinsic and can result from individual variations in patients and somatic cell genetic differences in tumors ([@bib0255]). Furthermore, acquired resistance has become common, by e.g. expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells before interaction with intracellular targets can occur, or acquired insensitivity to drug induced apoptosis and induction of drug-detoxifying mechanism ([@bib0255; @bib0250; @bib0585]). Hence, many cancer types e.g. malignant melanoma ([@bib0675; @bib0280]) show only slight sensitivity to anticancer drugs. Treatment with methylating antitumor agent dacarbazine and its oral equivalent temozolomide exhibits a response of only 15% ([@bib0120; @bib0475]). In metastatic melanoma, resistance is reported to be linked to defective apoptosis due to inhibition of expression of a gene encoding Apaf-1, the apoptotic protease activating factor-1 ([@bib0760]). A number of multidrug-resistant cancers have been detected and thus various approaches including the development of drugs that engage, evade or exploit efflux by ABC transporters have been described ([@bib0785]).

Despite all the progress in the design of cancer therapy there is still no cancer treatment that is 100% effective against disseminated cancer ([@bib0255]). By contrast, the overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be only 2.3% in Australia and 2.1% in the USA ([@bib0495]). Therefore, the development of new anticancer drugs based on novel mode of actions with improved cancer cell selectivity is urgently needed. Furthermore, patients suffering from cancer with poor treatability like glioblastoma, a cancer of the brain, do not survive longer than 1--2 years even if the cancer is detected early and treated with surgery, chemotherapy, and radiotherapy, ([@bib0095]). Stomach, ovarian and other cancers also demand new effective treatment.

3. Host defense peptides selectively targeting differences between cancer and non-cancer cell membranes {#sec0025}
=======================================================================================================

In the search for novel anticancer agents, host defense peptides have emerged as potential alternative anticancer therapeutics offering many advantages over other therapies. Because of their mode of action and specificity -- the cell membrane being the major target -- resistance and cytotoxicity are less likely to occur ([@bib0295; @bib0560; @bib0420; @bib0690]) and thus, they are also expected to cause fewer side effects. Furthermore, these peptides mostly damage cell membranes within minutes ([@bib0150]), which would hinder formation of resistance ([@bib0560]). Host defense peptides being part of the innate immune system of many diverse species (e.g. mammals, insects, amphibians) were initially discovered because of their antimicrobial activity ([@bib0915]). Currently, the antimicrobial peptide database lists more than 100 natural host defense peptides with antitumor activity ([@bib0850; @bib0840]). Selected host defense peptides for which *in vitro* studies were reported are listed in [Table 1](#tbl0005){ref-type="table"}. The most intensively studied antimicrobial peptides that also exhibit cytotoxic activity against cancer cells were described in detail in terms of structure, mode of action and anticancer activity in a recent review by [@bib0295]. These host defense peptides are characterized by low molecular weight (in the majority of cases less than 30 amino acids) as well as low antigenicity ([@bib0320]) and exhibit a predominantly cationic amphipathic structure making them prone to interact with anionic cell membrane surfaces ([@bib0400; @bib0395]). Indeed, various anionic molecules, discussed in the following, are more abundant on the surface of cancer cells as compared to non-cancer cells. This increased level of negative charge seemingly accounts for the selectivity of these membrane-active peptides towards cancer cells. In addition, one can envisage that anticancer peptides, which translocate to the cytosol, interact preferentially with the mitochondrial membrane owing to its high content of negatively charged lipids such as cardiolipin. As a consequence, the peptides may trigger apoptosis. Of note, mitochondrial membranes of different melanoma variants were shown to also contain significant amounts of phosphatidylserine ([@bib0685]). Furthermore, the susceptibility of cancer and non-cancer cells towards anticancer peptides is governed by differences in their membrane fluidity and/or by morphological changes such as the increased number of microvilli found on cancer cells. [Fig. 2](#fig0010){ref-type="fig"} outlines these and additional parameters such as acidification of cancer cell environment that may be of benefit in the anticancer activity of histidin-rich peptides as well as some important processes that suppress apoptosis in cancer cells.

3.1. Anionic phosphatidylserine exposed on the outer membrane leaflet of cancer cells {#sec0030}
-------------------------------------------------------------------------------------

Indeed, one of the major differences between cancer and non-cancer cell-surfaces is the exposure of the negatively charged lipid phosphatidylserine (PS) on the outer leaflet of the cancer cell membrane, which in non-cancer cells exhibits an overall neutral charge due to the zwitterionic phosphatidylcholine and sphingomyelin ([@bib0055]). Phosphatidylserine together with the major part of phosphatidylethanolamine is normally located in the inner leaflet of eukaryotic plasma membranes ([@bib0055]). This asymmetric distribution of the major phospholipids between the two membrane leaflets is well documented ([@bib0930; @bib0050]) and assumed to be maintained by ATP-dependent aminophospholipid translocase activity ([@bib0695]) and/or abolished by a Ca^2+^-dependent scramblase activity, which triggers non-specific movement of phospholipids to both leaflets ([@bib0930]). The loss of membrane asymmetry was demonstrated for several cancer types, revealing a promising uniform marker for cancer. Within some studies, PS exposed on the surface could even be visualized *in vitro* and *in vivo* by specific interaction with Annexin A5 and linked to a fluorophore ([@bib0170; @bib0780; @bib0645]). Since the pioneering work of [@bib0815] showing that tumourigenic cells expose 3--7-fold more PS than normal keratinocytes, PS exposure has been described for human ovarian carcinoma ([@bib0615]), human gastric carcinoma ([@bib0885]), different melanomas ([@bib0350; @bib0140]) and leukemias ([@bib0145; @bib0680]). In an extension of these studies, our laboratory focused on cancer with poor outcome and treatment efficacy including metastases as well as primary cell cultures and demonstrated that differently tumorigenic melanoma cell lines expose 4--11 times more PS than melanocytes ([Fig. 3](#fig0015){ref-type="fig"}), whereby the amount of exposed PS correlated with tumor progression ([@bib0940; @bib0640]). Furthermore, we proved that not only do cell lines derived from primary lesions and metastasis show PS on the outer leaflet of the cell membrane but also cells from primary cancer cell cultures. The number of different cancer types used in our study including (malignant) melanoma, a rhabdomyosarcoma, a malignant soft tissue tumor of mesenchymal origin, prostate cancer, renal cell cancer and a glioblastoma extended and strongly supported earlier findings, suggesting that PS exposure is a general phenomenon of cancer cells. In general, cells expressing PS in the outer leaflet of the plasma membrane are specifically recognized by the presence of macrophages ([@bib0235; @bib0445]) and dendritic cells ([@bib0005]) triggering apoptosis. However tumor cells, although exposing PS, circumvent apoptosis and prevent recognition by macrophages ([Fig. 2](#fig0010){ref-type="fig"}). For example, lung and colon cancer cells secrete elevated levels of a molecule that binds to FasL, a death activator on T-cells, and prevents them being killed. While melanoma inhibit expression of a gene encoding Apaf-1, the apoptotic protease activating factor-1, certain B-cell leukemias and lymphomas express high levels of Bcl-2, a protein that blocks apoptotic signals ([@bib0760; @bib0485]). Therefore, cationic host defense peptides, which show an excellent tumor tissue penetration reaching the site of both primary tumor and distant metastasis ([@bib0705]) and specifically interact with anionic membrane lipids ([@bib0935; @bib0950; @bib0405]), represent a promising approach in the development of novel anticancer drugs ([@bib0295; @bib0560; @bib0420; @bib0690]). It is also of interest to note that anionic phospholipids are also present on the surface of tumor blood vessels connected to tumor tissue ([@bib0610]). The observation of negatively charged tumor vasculature provides an additional potential target for anticancer peptides, which may be also used for imaging. For example, selective staining of vascular endothelium of different tumors and also tumor cells in and around regions of necrosis was shown using 9D2, a monoclonal antibody for anionic phospholipids or Annexin A5 ([@bib0610]). Furthermore, it is reported that radio-labeled Annexin A5 may allow for repeated and selective *in vivo* identification of apoptotic cell death without the need for invasive biopsy ([@bib0825]), which should also be applicable in the imaging of tumor tissue.

3.2. Enhancement of sialic acid residues on cancer cell surface {#sec0035}
---------------------------------------------------------------

Another source of negative charges on the surface of human cells is represented by sialic acid residues, which are linked to glycoproteins (e.g. mucins) and glycolipids. An overexpression of transmembrane mucins was shown e.g. for carcinoma cells from epithelia ([@bib0365; @bib0080]) and transmembrane mucin 1 (MUC1) was overexpressed in more than 90% of breast carcinomas and frequently in others such as ovarian, lung, colon and pancreatic carcinoma ([@bib0030]). The extent of surface sialylation seems to be directly correlated with the metastatic potential of different cancer cells exhibiting a protective function against the host immune system and facilitating migration and invasion via modulation of adhesiveness ([@bib0835; @bib0385; @bib0090]). The effect of different degrees of sialylation in terms of peptide interaction has been studied less intensively. For example, BMAP-27 and BMAP-28, host defense peptides from the cathelicidin family, exhibited lower activity on cancer cells when sialic acid had been cleaved off ([@bib0650]) suggesting that the outside charge seems to act as an initial interaction site for the peptides. By contrast, in a preliminary study performed in our laboratory the activity of peptides derived from a fragment of human lactoferricin, was unaffected by cleavage of sialic acid moieties of a rhabdomyosarcoma (unpublished data), suggesting something other than sialic acid as a preferred target for this tumor type. Summarizing, it is obvious that glycosylation plays an important role in the interaction with peptides. For more details about changes in the glycosylation pattern in cancer cells and impact on cell processes like cancer progression and impairment of signaling pathways see [@bib0295].

3.3. Heparan sulfate {#sec0040}
--------------------

In addition to the above mentioned sources of negative charges on the surface of cancer cells, the role played by proteoglycans should also be noted ([@bib0355]). These proteins contain highly negatively charged glycosaminoglycan side chains mainly in the form of heparan sulfate and chondroitin sulfate composed of linear repeats of sulfated disaccharides ([@bib0775; @bib0800]). These disaccharides contain a high number of sulfate groups yielding highly negatively charged molecules ([@bib0605]). It has been reported for several cancer cells that proteoglycan expression and sulfation is altered ([@bib0330; @bib0360; @bib0665; @bib0450; @bib0670; @bib0025; @bib0510]). [@bib0225] reported that chondoitrin sulfate had no effect on the activity of bovine lactoferricin (bLFcin), which however was improved after depletion of heparan sulfate on cancer cells and lowered upon addition of exogenous heparan sulfate. Although this observation seemingly implies that heparan sulfate may inhibit the activity of anticancer peptides, the same group showed recently that small lytic peptides derived from bLFcin are not affected by heparan sulfate or even possess increased activity in their presence ([@bib0230]).

3.4. Altered membrane fluidity in cancer cell membranes {#sec0045}
-------------------------------------------------------

Apart from changes in the pattern of the surface charge, membrane fluidity also appears to be altered in tumorigenic cells, though it is not clear if this alteration is uniform throughout all carcinomas. The majority of studies indicate increased fluidity of the cancer cell membrane as described for lymphomas, lung carcinomas and neural tumors ([@bib0720; @bib0765; @bib0070; @bib0655]). By contrast, it has been reported that cells from solid tumor tissues (e.g. hepatoma) exhibit a lower membrane fluidity than their healthy counterparts ([@bib0820]). In this context it is important to note that Sherbet et al. ([@bib0725]) already suggested that membrane fluidity is not uniform all over the cell itself. This is in accordance with more recent observations showing that some breast and prostate cancer cell lines possess elevated levels of cholesterol-rich lipid rafts, raising the question if in fact only some parts of the cancer membrane comprise increased fluidity by different lateral lipid arrangement ([@bib0375]). In the case of unaltered total cholesterol content, this would imply a cholesterol-depleted bulk membrane harboring PS that may exhibit higher susceptibility to peptide attack because of its increased fluidity and hence less tightly packed lipids. Interestingly, the metastatic cascade also seems to be influenced by alterations in membrane fluidity. Thus, increased fluidity was reported for metastatic cells ([@bib0515]) due to differences in the cholesterol to phospholipid ratio ([@bib0685]). According to some reports, resistance to drugs also seems to be related to cell membrane fluidity. [@bib0465] for example reported that vinblastine resistant leukemic cells possess 50% more cholesterol, corresponding to decreased fluidity, than vinblastine sensitive cells. This finding is supported by higher cholesterol levels in multidrug-resistant ovarian cancer cells ([@bib0470]). It is evident that knowledge of membrane fluidity (with cholesterol content only being one parameter alongside degree of hydrocarbon chain saturation etc.) should be regarded as an important physical membrane parameter that interferes with insertion of amphipathic peptides being facilitated in more fluid membranes.

3.5. Microvilli increasing the cell surface area of cancer cells {#sec0050}
----------------------------------------------------------------

Another important difference between cancer and non-cancer cells is the increase in surface area of tumorigenic cells, triggered by the increase of microvilli on these cells ([@bib0930; @bib0560; @bib0175; @bib0125]). This should be beneficial in the application of membrane-active peptides since efficiency can be increased by enabling the binding of a larger amount of peptides per cell ([@bib0930; @bib0560]). Support for this notion comes from a comparative study on the cytolytic effect of cecropin B on tumor cells such as KG-1 leukemia and Ags stomach carcinoma and non-tumor cells like fibroblasts and red blood cells, which demonstrated that the peptide was more effective on the cancer than normal cells ([@bib0105]). Based on scanning electron microscopy data, it was suggested that this may mainly be due to the high population of irregular microvilli on the cell surface of the cancer cells and that the attraction of peptides by microvilli may be one of the main driving forces before membranolysis can be efficiently initiated.

In summary, accumulation of cationic amphipathic peptides will be triggered by the presence of anionic components on the cell surface as well as by the increase in cell surface owing to increased number of microvilli, while insertion of peptides will be mainly governed by membrane fluidity, which in eukaryotic membranes is largely regulated by its cholesterol content. Therefore, the differences in lipid composition and morphology of cell membranes govern the interaction with membrane-active peptide and furthermore, may also be related to the varying susceptibility of different types of cancer cells against a certain antitumor peptide ([@bib0370; @bib0425]).

4. Mode of action of anticancer peptides {#sec0055}
========================================

Two general mechanisms, triggering necrosis or apoptosis by anticancer peptides as a consequence of their membrane related mode of killing of cancer cells, have been discussed ([@bib0560; @bib0060; @bib0690]). Both killing based on necrosis via cell membrane lysis and apoptosis via the mitochondrial lytic effect seems to be dependent on the presence of anionic lipids. As described in Section [3.1](#sec0030){ref-type="sec"}, negatively charged PS located in the outer leaflet of cancer cells can represent such a specific target, e.g. cardiolipin, a major anionic phospholipid of the mitochondrial membrane. Other sources of negatively charged molecules which are also exposed and often overexpressed on non-cancer plasma membranes such as sialylated glycoproteins or heparan sulfate proteoglycans should also be considered when considering the activity and efficacy of cationic anticancer peptides. However, their influence has been studied less systematically and seemingly contradictory effects have been reported in terms of anticancer activity of the peptides (see Sections [3.2 and 3.3](#sec0035 sec0040){ref-type="sec"}). A major role of PS may be deduced from the selective binding of the synthetic host defense-like membranolytic peptide, \[[d]{.smallcaps}\]-K~6~L~9~, to PS, which was demonstrated by co-localization of PS and peptides on the outside of cancer cells ([@bib0565]). The authors thus suggested that the selectivity of the peptide towards cancer cells stems largely from its binding to surface exposed PS and that killing of the cancer cells occurs via cytoplasmic membrane depolarization. Consequently, it appears that for effective disruption of the cell membrane, peptide--lipid interaction is the crucial step which the peptides need in order to meet the proper structural requirements. Thus, in order to engineer more potent antitumor peptides in respect of efficacy as well as selectivity and thus reduced toxicity, it is necessary to further unravel their molecular mode of action.

Furthermore, non-membrane related mechanisms have been considered. For example, stimulation of NK cells as well as interferon synthesis by the insect antimicrobial peptide alloferon ([@bib0135]) or the transcriptional inhibitory effect of melittin and cecropin ([@bib0880]) were regarded as being probably due to an indirect mechanism, which is mediated by the ability of the cytolytic peptide to interfere with signal transduction pathways. Tachyplesin conjugated to an integrin homing domain ([@bib0570; @bib0130]) was further shown to interact with the mitochondrial membranes of cancer cells and to up-regulate members of the death receptor pathway, which suggests that this peptide-conjugate also has more than one effect on cancer cells. Therefore, [@bib0560] proposed that these observations may imply that in addition to their being active on their own cytolytic peptides may activate or act synergistically with other host defense components in order to clear tumors. Nevertheless, since killing takes place very rapidly it seems quite reasonable to assume that a non-receptor mediated membranolytic killing mechanism is responsible for the majority of anticancer peptides derived from host defense peptides.

4.1. Membrane related molecular mechanisms of cell killing {#sec0060}
----------------------------------------------------------

The discovery that naturally occurring antimicrobial peptides mostly kill bacteria by damaging their cell membrane has initiated much effort in the detailed study of peptide--membrane interaction. The concept of a characteristic lipid composition for a given cell membrane is well accepted and hence the different physicochemical properties of the lipids found in biological membranes allow host defense peptides to discriminate between e.g. bacterial, cancer and non-cancer cell membranes ([@bib0405; @bib0645; @bib0390]). In a simplified view, these cationic amphipathic peptides will exhibit a higher affinity to cell membranes that expose negatively charged lipids on their outer membrane leaflet. The molecular mechanism(s) of membrane damage mutually depends on the nature of both peptides and membrane lipids ([@bib0700]).

Several models ([Fig. 4](#fig0020){ref-type="fig"}) have been suggested to explain their biological activity (for reviews see e.g. [@bib0400; @bib0395; @bib0045; @bib0865]). The most frequently discussed mode of action includes the formation of toroidal pores ([@bib0455; @bib0415]) and the carpet model ([@bib0710]). In the toroidal pore model peptides, together with the lipid, assemble into a supra-molecular arrangement of high curvature forming a water-filled pore. Although a number of molecules including α-helical and β-sheet type peptides have been shown to adopt such a pore under the given experimental conditions ([@bib0305]), there is little evidence that the majority of these peptides act *in vivo* via transmembrane pores ([@bib0870]). The carpet model is most commonly cited when explaining membrane disintegration by a non-pore model. In this model, the amphipathic peptides accumulate at the membrane being aligned parallel to the bilayer surface. Once this "peptide carpet" becomes too dense, membrane permeabilization occurs via destabilization of the membrane bilayer ([@bib0710]). Thereby, at the molecular level different scenarios may apply, which were recently summarized in an excellent review by [@bib0865]. Briefly explained, membrane permeabilization has been proposed as being due to (a) peptide induced clustering or phase separation of lipids creating defects at the peptide-rich and peptide-poor domains ([@bib0395; @bib0205; @bib0210; @bib0215; @bib0410; @bib0950]), (b) the sinking raft model, which allows a formal thermodynamic analysis to predict membrane perturbation ([@bib0595; @bib0600; @bib0260; @bib0010]), (c) disruption of the normally strict segregation of polar and non-polar groups of the lipids driven by the partitioning of an imperfectly amphipathic peptide into the bilayer interface ([@bib0620; @bib0625]) or (d) a detergent-like action in particular at high peptide concentration ([@bib0300; @bib0040; @bib0545]). Furthermore, a complex generic phase diagram has recently been developed rationalizing the membrane interactions of cationic amphipathic peptides by their molecular shape to explain in a more general sense the mode of action of these cationic amphipathic peptides ([@bib0040; @bib0045]). Besides electrostatic interactions, molecular properties of lipids such as their molecular shape and being related to the spontaneous curvature are known to play a significant role for the aggregation state of lipids ([@bib0315; @bib0440; @bib0045]) and, thus, also to affect interactions of these assemblies with membrane-active peptides. In fact in terms of structural membrane changes, insertion of antimicrobial peptide molecules, some of them also exhibiting antitumor activity such as NK-2 ([@bib0680]) or lactoferricin derivatives ([@bib0645]), promoted the formation of inverted hexagonal or bi-continuous cubic phases in membrane mimetic systems ([@bib0770; @bib0860; @bib0285; @bib0945; @bib0950]).

Furthermore, solid tumors are discussed as exhibiting an acidic extracellular environment (for a review see [@bib0265]). This acidification seems to be a consequence of lactic acid accumulation, which is produced during aerobic and anaerobic glycolysis and, due to inadequate vasculature in growing tumors, its insufficient removal. However, lactic acid accumulation does not seem to be the only reason for the acidification of the extracellular environment of tumors. [@bib0520] reported that glycolysis-deficient cells are also more acidic than cells from normal tissues without accumulating lactic acid above serum levels. In any case, an acidic tumor environment might be a useful "activation" switch for anticancer peptides comprised of amino acids like histidine, which are only positively charged and thus active at low pH ([@bib0430]). Such an approach was reported for the synthetic host defense-like lytic peptide \[[d]{.smallcaps}\]-K~6~L~9~, where the lysine residues were exchanged by histidine, resulting in reduced systemic toxicity compared to the parent peptide. It was suggested that the pH-dependent activity and lytic mode of action of the His-rich peptide, in hindering development of resistance, will make them potential candidates for treatment of solid tumors. In fact, intra-tumor and systemic inoculation of (\[[d]{.smallcaps}\]-H~6~L~9~) significantly reduced the 22RV1 prostate cancer tumor size in a xenograft mice model ([@bib0430]).

In the context of taking advantage of the acidic environment of solid tumors it is worthwhile reporting on pHLIP (pH (Low) Insertion Peptide), a peptide derived from the C-helix of bacteriorhodopsin, although this peptide neither displays a membranolytic mechanism nor is it derived from a host defense peptide. pHLIP shows interesting pH-sensitive properties in that it only forms a transmembrane helix in the acidic environment of solid tumors, whereas at neutral or high pH it is in equilibrium between an unstructured form and bound to the surface of a lipid bilayer ([@bib0310; @bib0635]). pHLIP itself does not exhibit direct toxicity to cells ([@bib0630]) or mice ([@bib0020]) at concentrations below 50 μM, however, the peptide in its helical form possesses useful drug delivery efficiency facilitating translocation of cell-impermeable polar molecules into the cytoplasm ([@bib0630; @bib0635; @bib0020; @bib0925; @bib0795]). One example of efficient drug delivery into cancer cells through translocation with pHLIP is phalloidin toxin, which inhibits cancer cell proliferation after cleavage from pHLIP inside the cells ([@bib0015]).

4.2. Non-membrane related mechanisms {#sec0065}
------------------------------------

Here, we briefly summarize some mechanisms, which do not involve permeabilization/disruption of plasma or mitochondrial membranes in cancer cells. There is growing evidence that the antimicrobial activity of host defense peptides is not solely related to cell membrane damage but some act caused by immunomodulatory effects ([@bib0275; @bib0185; @bib0855]). Little knowledge is so far available as to whether this may also be the case for the antitumor activity of these cationic amphipathic peptides. In particular in the case of cancers where the immune response is often diminished or strongly suppressed, it was suggested that cancer therapies might be supported by the simultaneous administration of immunoadjuvants, which activate both an innate and acquired immune system response ([@bib0180]). Although many small peptides of microbial origin possess a non-specific immunostimulatory response (for a review see [@bib0690]), reports on an immunomodulatory effect of host defense peptides in cancer cells are rare. One example are alloferons, histidine-rich peptides from insects shown to stimulate natural killer cells of human peripheral blood lymphocytes and to induce synthesis of interferon in mice models ([@bib0135]). This cytokine-like modulating property resulted in antitumor resistance.

Specific targets have so far only been reported for a few anticancer peptides. PR-39, a peptide of the cathelicidin family which is rich in proline and arginine residues, can translocate into the cytosolic compartment of cells without permeabilizing the plasma membrane where it interacts with proteins containing SH3-binding motifs ([@bib0110; @bib0790]). Experiments using derivatives of PR-39 indicated that the N-terminal arginine is crucial for binding to the SH3-domain and subsequent induction of syndecan-1 production ([@bib0115]). Indeed, elevated levels of syndecan-1 were observed in treatment of human hepatocellular carcinoma cells with either PR-39 or upon transfection of this cell line with the PR-39 gene ([@bib0535]). Expression of syndecan-1 has been related to inhibition of cell invasion ([@bib0380]) and thus it was suggested that this linear cationic peptide may suppress the invasive activity of these cancer cells therefore preventing metastasis ([@bib0535]). Another target of many anticancer drugs is tubulin, which was also shown to be the site of action for linear peptides derived from the host defense-like peptide dolastatin 10 (US Pat. No. 4,816,444) or dolastatin 15 (EP-A-398558) ([@bib0745]). Thereby, the mechanism of action, as for all antitumor tubulin ligands, involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis ([@bib0155]).

Finally, a specific case was reported for bee venom melittin, which preferentially counter-selects mammalian cells with the overexpressed *ras* oncogene, where it acts through hyperactivation of phospholipase A~2~ ([@bib0715]). It should be noted, however, that melittin is also known for its toxicity to mammalian cells (e.g. ([@bib0270])). In fact, for *in vivo* studies a melittin/avidin conjugate was used, which did not exert its anticancer activity by membranolysis but by targeting cancer cells with high matrix metalloproteinase 2 ([@bib0290]) as described in Section [5.2](#sec0080){ref-type="sec"}.

5. *In vivo* studies of anticancer peptides {#sec0070}
===========================================

Based on successful *in vitro* experiments, a number of peptides have also been tested *in vivo* to explore their therapeutic potential ([Table 2](#tbl0010){ref-type="table"}). In addition to the administration of anticancer peptides *per se*, strategies have been developed that may improve pharmacokinetics and/or selectivity and hence reduce toxicity. This includes the application of vector-mediated delivery of genes encoding membranolytic peptides and the use of homing domains transporting the anticancer peptides into the cytosolic compartment of cancer cells. Some of the respective *in vivo* studies are briefly described below.

5.1. Anticancer activity of peptides related to membrane damage {#sec0075}
---------------------------------------------------------------

Magainins, originally isolated from the skin of the African clawed frog, *Xenopus laevis* ([@bib0910]), were among the first peptides to be tested for their *in vivo* anticancer activity. Magainin 2 was shown to exhibit an amphiphilic α-helical structure that facilitates the formation of ion-permeable pores in membranes, consequently inducing depolarization and cytolysis ([@bib0150]). [@bib0035] demonstrated that magainin analogues were able to elevate the survival level of animals with ascites-producing tumors. Furthermore, magainin 2 has been tested for local treatment in a subcutaneous xenograft model of melanoma in nude mice, where it completely eliminated the tumor with only minimal damage to surrounding tissue ([@bib0755]).

Another prominent member of anticancer peptides is bovine lactoferricin ([@bib0245]), which is generated from lactoferrin through pepsin cleavage. Unlike magainins, bLFcin possesses an acyclic twisted antiparallel β-sheet structure due to a disulfide bridge between two cysteine residues ([@bib0830]). Systematic studies on bLFcin derivatives revealed some parameters of importance for antitumor activity such as the need for high net positive charge (+7 as compared to +4 for antimicrobial activity) and clear cationic and hydrophobic sectors (amphipathicity) ([@bib0900; @bib0895]). Furthermore, the requirement of a stabilized secondary structure may be deduced from the higher activity of the cyclic peptide ([@bib0200]), which showed a clearer partitioning of the cationic and hydrophobic faces ([@bib0530]). As this property is less important for antimicrobial activity, it was suggested that it indicates a constraint for the peptide to traverse mammalian membranes ([@bib0245]). [@bib0905] demonstrated that the peptide inhibits liver and lung metastasis in mice. Additionally, bLFcin showed antiangiogenic activity leading to suppression of tumor growth. *In vivo* studies with bLFcin on fibrosarcoma, melanoma and colon carcinoma tumors revealed massive necrosis of the tumor tissue after exposure to the peptide ([@bib0200]). [@bib0195] also showed that bLFcin significantly inhibits tumor growth of neuroblastoma xenografts in nude rats. Clarification of the mechanism revealed that bLFcin induces apoptosis in human tumor cells through a pathway mediated by production of the intracellular ROS and activation of Ca^2+^/Mg^2+^-dependent endonucleases ([@bib0905]), which was partially confirmed by studies carried out by [@bib0425], who also documented the mitochondrial pathway of apoptosis for bLFcin. Other studies reported that induction of apoptotic or necrotic cell death was dependent on the concentration of the peptide ([@bib0540; @bib0195]). Recently, it was shown that *in vitro* treatment with bLFcin killed Raji and Ramos human B-lymphoma cells via a caspase-independent apoptotic pathway being more efficient at low serum concentration of the peptide ([@bib0240]). Notably, in the presence of exogenous bovine serum albumin the activity was inhibited, which suggests partial neutralization of the cationic peptide by anionic serum components as described earlier for the inhibition of the tumoricidal activity of amphiphilic alpha helical peptides ([@bib0580]). Nevertheless, immune-deficient SCID/beige mice exhibited extended survival using systemic administration of bLFcin underlining the potential of this peptide for further development as novel anticancer agent.

Gomesin (Gm), an antimicrobial peptide isolated from the hemocytes of the unchallenged Brazilian spider *Acanthoscurria gomesiana*, also exhibits anticancer activity ([@bib0740]). This cationic peptide adopts a hairpin-like two-stranded antiparallel β-sheet structure, which is maintained by two internal disulfide bridges ([@bib0435]). Topical treatment of subcutaneous murine melanoma with gomesin significantly retarded tumor growth and increased the number of animals with tumors below a critical size ([@bib0660]). Importantly, Gm did not exhibit any toxic effect on the peripheral healthy skin of mice after repeated applications of the peptide. Gm does not kill tumor cells through apoptosis but rather through induction of morphologic cell alterations with increased granularity, loss of cytoplasmic content by membrane permeabilization, and partial collapse of the proton gradient ([@bib0660]).

Polybia-MPI (MPI) is an anticancer peptide derived from the venom of social wasp *Polybia paulista*. In order to improve the activity and stability of MPI, the C-terminal amide of the peptide was replaced by a thioamide group (MPI-1) ([@bib0920]). Indeed, MPI-1 is more efficient in suppresssing tumor growth of sarcoma xenograft in mice than MPI, which was attributed to its higher serum stability. However, the modification did not affect the cytotoxic behavior of the peptide. *In vitro* studies provide evidence of killing caused by necrosis as a result of acute cell injury, swelling and bursting via disruption of the membrane or formation of transmembrane pores ([@bib0845]).

An alternative approach for *in vivo* use of membranolytic peptides to maintain therapeutic levels and reduce cytotoxicity was suggested by [@bib0880] and involving the introduction of vector-mediated delivery of genes encoding cecropin or melittin into a human bladder carcinoma derived cell line ([@bib0880]). The resultant cell clones were analyzed for tumorigenicity in nude mice showing that expression of cecropin resulted in either a complete loss of tumorigenicity in some clones or reduced tumorigenicity as measured by latency of tumor formation. Similarly, a plasmid that expressed secretable human α-defensin-1, also known as the human neutrophil peptide-1 (HNP1) was used in gene therapy of a human lung adenocarcinoma xenograft in nude mice ([@bib0890]). In this study, [@bib0890] showed that HNP1 can be intracellularily expressed in tumor cells resulting in significant inhibition of tumor growth by induction of apoptosis.

5.2. Anticancer agents based on anticancer peptide-conjugates {#sec0080}
-------------------------------------------------------------

Melittin, extracted from the European honey bee *Apis mellifera*, is a mostly α-helical peptide assumed to induce cell lysis by pore formation ([@bib0810; @bib0460]). Since melittin is highly toxic to red blood cells and untransformed cells, a melittin/avidin conjugate was designed to gain an inactive peptide towards healthy cells as it specifically targets cancer cells with high matrix metalloproteinase 2 (MMP2) activity ([@bib0290]). MMP2 is known to be overexpressed in several cancers and tumor microvascular endothelial cells and has the ability to reactivate peptide activity by cleavage of the conjugate at the tumor site. *In vivo* studies showed that the size of B16 tumors in mice decreased significantly after treatment with the melittin/avidin conjugate. Activity of the conjugate most probably arises from its ability to target tumor vasculature since the level of cell lysis in cultured cells was relatively low ([@bib0290]).

Tachyplesin, a peptide isolated from hemocytes of the horseshoe crab (*Tachypleus tridentatus*), exhibits a structure with exposed basic amino acids on the peptide surface ([@bib0505]), which enables binding to anionic phospholipids ([@bib0570; @bib0345]). The peptide was shown to have anticancer activity *in vivo* in a B16 mouse model ([@bib0130]). In this study, a synthetic tachyplesin was conjugated to the integrin homing domain RGB, which enables internalization of the peptide.

5.3. Anti-proliferative peptides {#sec0085}
--------------------------------

Dolastatin 10 (US Pat. No. 4,816,444) derived from the family of dolastatins, a peptide isolated from the marine shell-less mollusk *Dolabela auricularia*, completed Phase II trial against indolent lymphoma, Waldenstrom\'s macroglobulinemia and chronic lymphocytic leukemia in 2000 ([@bib0745]). At the time of discovery it was shown to be the most potent anti-proliferative agent against murine PS leukemia cells ([@bib0590]). Eventually, the peptide had to be dropped from clinical trials because of moderate peripheral neuropathy in 40% of patients. Therefore, derivatives of dolastatin 10, like TZT-1027 (Soblidotin) ([@bib0490]) or of dolastatin 15 (antimitotic), like ILX-651 (Synthadotin) ([@bib0190]), which show reduced toxicity but yet potent antitumor activity have been further explored in clinical studies.

6. Challenges for the development of host defense peptides as novel anticancer agents {#sec0090}
=====================================================================================

Interestingly, despite numerous successful *in vivo* studies none of the membrane-active host defense peptides has so far made it on to the market. There may be several reasons for this and their development as novel anticancer agent may predominantly be hampered by the poor bioavailability and potential toxicity of such peptides ([@bib0275]). Peptide degradation in serum owing to the presence of proteases is a major obstacle, which besides unspecific binding to serum components also limits the half time of these molecules in serum. In order to improve the pharmacodynamic properties, different strategies may be applied to achieve enhanced cell specificity and serum stability.

6.1. Enhancing selectivity to further reduce cytotoxicity {#sec0095}
---------------------------------------------------------

Not all host defense peptides showing antitumor activity are sufficiently selective against cancer cells. Accordingly, a more detailed knowledge of their structure--activity relationship is required in order to understand the molecular peptide parameters for the design of promising novel antitumor agents. As outlined above, host defense peptides exhibit great structural diversity yet share some common features. They are typically 10--40 amino acids long and positively charged (net charge of +2 to +9). While differing in the percentage of hydrophobic residues, these peptides share an amphiphilic character, i.e. they have the ability to adopt a structure in which hydrophobic and polar/charged residues are spatially organized in discrete sectors of the molecule. Although host defense peptides belong to different structural classes, they often exhibit an intrinsic flexibility and structural adaptability, which are thought to be responsible for different modes of interaction with membrane bilayers ([@bib0335]). Thus net charge, amphipathicity, hydrophobicity, and structural propensity are among the most important physicochemical and structural parameters that govern the ability of these peptides to interact with cell membranes. A statistical analysis of the antitumor peptides listed in the Antimicrobial Peptide Data Base ([@bib0850; @bib0840]) in terms of secondary structure, length of the peptide, distribution of charged and hydrophobic amino acid residues and determination of hydrophobicity expressed as transfer free energy of peptides from water to *n*-octanol (Δ*G*~woct~) ([@bib0875]) show that these parameters can vary within a wide range ([Fig. 5](#fig0025){ref-type="fig"}). It is interesting to note that there is still a large fraction of peptides with unknown structure (∼39%) being comparable to the fraction of peptides with α-helical structure (∼34%), which seems to be the predominant one. However, as can be deduced from [Tables 1 and 2](#tbl0005 tbl0010){ref-type="table"} there have been not less peptides tested successfully in *in vitro* and *in vivo* studies, which exhibit a β-sheet structure, although these peptides account only for ∼2% of the total antitumor peptides listed. Pair correlations between peptide length and charge as well as peptide length and hydrophobicity indicate again that even for a given peptide length these parameters can vary widely being more apparent for the distribution of the net charge ([Fig. 6](#fig0030){ref-type="fig"}). For a meaningful interpretation of these data one would also need to consider the antitumor activity and cell specificity of the peptides. However, this cannot be performed on this set of data, as the peptides listed in the Antimicrobial Peptide Data Base ([@bib0850; @bib0840]) were tested against different cancer cells and healthy mammalian cells using also different protocols. But a cluster analysis of a database of 158 amphipathic α-helical peptides, from which the activity spectrum was determined, revealed structural characteristics of anticancer peptides ([@bib0165]). This database was constructed using data presented by Owen (US Patent 6,875,744), and contained 14 peptides, which showed selectivity for cancer cell lines only, 123 peptides showing cytotoxicity also to non-cancer cells and 21 inactive peptides. Three-dimensional clustering techniques were used to group these peptides with respect to similarity in net positive charge, hydrophobicity and hydrophobic moment producing 21 clusters. The observation that the inactive peptides were found across seven clusters highlights the fact that these three parameters alone cannot be used as predictors of activity. However, as hydrophobicity of peptides is important for membrane penetration, an extended hydrophobic moment plot analysis was also performed. Although peptides with arc sizes \>270° appeared to be less toxic, statistical analysis was unable to establish a direct correlation between arc size and toxicity. Furthermore, using this approach it was predicted that over 50% of the active peptides would be surface active. This suggests that amphiphilicity is a key driver of the membrane interactions for these peptides. Thereby, peptides showing cancer cell specificity fell within a narrow range of amphiphilicity of 0.53--0.78 and had no tilted helical peptide structure, which within the analysis was more commonly found for peptides being toxic to both cancer and non-cancer cells. Such a tilted structure has already been previously associated with relatively non-specific means of cell membrane lysis ([@bib0295]). This cluster analysis in conjunction with an earlier study carried out by the same group ([@bib0160]) suggests that the interplay of a range of physicochemical characteristics rather than any single overriding factor determines the biological activity of these peptides. Furthermore, to add to the complexity of the system one must bear in mind that the lipid composition of the target membrane should not be neglected as it in turn strongly affects the penetration behavior of peptides. Therefore, application of newly developed technologies for high-throughput screening as recently described in regard to antimicrobial peptides ([@bib0065]) may be beneficial in unraveling the molecular parameters making anticancer peptides more suitable for clinical use, i.e. exhibiting high specificity and activity, low susceptibility to proteolysis and reduced toxicity.

6.2. Improving serum stability {#sec0100}
------------------------------

The *in vivo* potency of antitumor peptides is often hindered by proteolysis of the peptides, which reduces their half time in serum and hence bioavailability. One strategy used to overcome this problem is the application of vector-mediated delivery of genes that encode the active anticancer peptide ([@bib0880]) as outlined in Section [5.1](#sec0075){ref-type="sec"}. Another simple but efficient modification is the incorporation of [d]{.smallcaps}-amino acids or the replacement of all naturally occurring [l]{.smallcaps}-amino acids by its diastereomer ([@bib0560]). Early studies on magainin 2 and its all [d]{.smallcaps}-amino acid analogue MSI-238 demonstrated the feasibility of this approach ([@bib0035]). Both peptides were found to be active against P388 leukemia, S180 ascites and spontaneous ovarian tumor of mice upon intra-peritoneal injection of peptides, but with the all-D peptide showing significantly higher *in vitro* activity than the all-L peptide ([@bib0035]). A series of studies were initiated using systematically de novo-designed antimicrobial peptides composed of both [d]{.smallcaps}- and [l]{.smallcaps}-amino acids mimicking the lytic activity of host defense peptides ([@bib0555]). The resulting diastereomeric peptides lost their cytotoxic effect against normal cells but preserved anticancer activity with reduced serum inactivation and enzymatic degradation *in vivo*. For instance, one specific diastereomer composed of 15 amino acids (\[[d]{.smallcaps}\]-K~6~L~9~) showed selectivity to primary and metastatic tumors in human prostate and breast xenografts when administered systemically ([@bib0550; @bib0565]). A histopathological evaluation revealed that the diastereomer did not cause any damage to organs of mice emphasizing the potential for such peptides to be developed for therapeutic application.

7. Perspectives {#sec0105}
===============

Cancer treatment with chemotherapeutics still has many severe side effects and can induce drug resistance thus adversely affecting their successful use. Therefore, novel therapeutic approaches with improved cancer cell selectivity and thus reduced toxicity as well as hindered resistance development are urgently needed as has been observed for membrane-active host defense peptides in a number of *in vivo* studies (see Section [5](#sec0070){ref-type="sec"}). It is also advantageous that they have excellent tumor tissue penetration, which enables them not only to reach primary but also metastatic tumor sites. However, despite the wealth of information the molecular basis for selective targeting of cancer cells and the mechanism of cell killing by host defense peptides remain questions to be solved. Since there is a wide variety of host defense peptides yet many of them do not possess sufficient antitumor activity, optimization of peptides including innovative types of peptide modification to fine-tune their selective interaction with their target cell membrane together with a profound knowledge of their characteristic lipid composition are needed in order to attain a highly active and specific peptide. Biophysical studies considering the peptides as well as membrane characteristics will provide new insights for the rationale design of anticancer peptides. The progress may be facilitated by recent advances in high-throughput screening techniques that can also be implemented in academic laboratories. Based on such knowledge, the field of peptidomimetics may offer alternative means for the development of anticancer drugs with optimized pharmacodynamic profiles. In conclusion, these strategies are expected to yield novel anticancer drugs with improved properties with respect to selectivity and thus reduced toxicity, as well as to hindered development of drug resistance. These peptides may also be used in combination with chemotherapeutics as some peptides have shown synergy with classical chemotherapy ([@bib0560]). Achieving this goal would represent a major advancement in cancer treatment.
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![New anticancer drugs (1940s-06/2006) subdivided by source adapted from ([@bib0525]): (B) biological; (N) natural product; (ND) derived from natural product -- semisynthetic modifications; (S) synthetic drug; (S/NM) synthetic/natural drug mimic; (S\*) made by total synthesis; (S\*/NM) made by total synthesis/natural drug mimic; (V) vaccine.](gr1){#fig0005}

![Sketch of specific characteristics of cancer cells concerning membrane and genetic changes. Selectivity of cationic anticancer peptides can be driven by direct interaction with anionic target molecules exposed on the cell surface such as PS. Exposure of PS (1) is related to several cell processes, which involves activation of a putative scramblase and inactivation of a putative ATP-dependent phospholipid (PL) -- translocase. Increased levels of sialic acid of glycolipids and proteins on cancer surfaces (2), normally providing a protective shield, can also be a target for the positively charged peptides. Furthermore, changes in membrane fluidity (3) and pH (4) influence susceptibility and activity of peptides, which may also be affected by the increased surface area of cancer cells owing to the higher number of microvilli (5) present. Finally, peptides, which translocate into the cytosolic compartment, may interact with anionic lipids of mitochondria, triggering apoptosis, a process normally blocked by several changes in tumor cells such as e.g. inactivation of the tumor suppressor p53 (6). For details see main text.](gr2){#fig0010}

![PS exposure of melanoma cell lines: correlation of PS exposure with tumor progression of melanoma cell lines expressed as multiples of PS exposure of normal melanocytes as determined by Annexin A5 binding (SBcl-2, WM35 from primary and WM9, WM164 from metastatic lesions; error bars resulting from four independent experiments).](gr3){#fig0015}

![Mode of action of membrane-active host defense peptides: boundaries of the schematic phase diagram of amphipathic peptide/phospholipid aggregates are given as a function of the concentration of membrane-associated peptide and the composition of the membrane from mixtures of cylindrical (phosphatidylserine, phosphatidylcholine) and truncated inverted cone lipids (cardiolipin, phosphatidylethanolamine); modified from [@bib0045]. Membrane association of the cationic peptides is strongly increased in the presence of anionic phospholipids such as PS or cardiolipin. In the presence of cholesterol, an abundant membrane component in mammalian cells, the bilayer will be stabilized, i.e. the phase region of stable bilayers will be enhanced. Some molecular mechanisms of bilayer perturbation are schematically shown (for details see Section [4.1](#sec0060){ref-type="sec"}).](gr4){#fig0020}

![Characteristics of anticancer peptides: (A) peptide length; (B) net charge; (C) hydrophobic content (% hydrophobic amino acids; <http://aps.unmc.edu/AP/design/design_improve.php>); (D) hydrophobicity of peptides expressed as transfer free energy of peptides from water to *n*-octanol (Δ*G*~woct~) taking into account the contribution of both endgroups (COO^−^ and NH~3~^+^), in case of C-amidation or N-acetylation Δ*G*~woct~ decreases by 3.6 kcal/mol and 2.3 kcal/mol, respectively (<http://blanco.biomol.uci.edu/mpex/>) ([@bib0875]), n.c., not calculated for peptides \>70 amino acids; (E) structural characteristics.](gr5){#fig0025}

![Pair correlations between peptide length and net charge (A) and hydrophobicity (B), respectively, for antitumor peptides listed in the Antimicrobial Peptide Database, APD2 ([@bib0840]) excluding the three peptides \>70 amino acids for which no Δ*G*~woct~ can be calculated. The secondary structure of the individual peptides is indicated in the panels by the following symbols: ♦, α-helix; ■, β-sheet; ▴, α-helix and β-sheet; ●, unknown; ×, others.](gr6){#fig0030}

###### 

Selected host defense peptides tested in *in vitro* studies for anticancer activity.[a](#tblfn0005){ref-type="table-fn"}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peptide/*Source*                        Sequence                                                  *In vitro* study
  --------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  α-Helical                                                                                         

  Aureins\                                GLFDIIKKIAESF\                                            60 cancer cell lines tested (human tumor line testing program of the US National Cancer Institute) (∼50 active) ([@bib1030])
  *Southern bell frog*                    (aurein 1.2)                                              

  BMAP-27/BMAP-28\                        GRFKRFRKKFKKLFKKLSPVIPLLHLG/\                             Human tumor cells, leukemic cells ([@bib0650])
  *Bovine*                                GGLRSLGRKILRAWKKYGPIIVPIIRIG                              

  Cecropin A\                             KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK\                    Bladder cancer ([@bib1040])\
  *Hyalophora cecropia*\                  KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL                       Leukemia ([@bib0955]), bladder cancer ([@bib1040])
  Cecropin B\                                                                                       
  *Chinese oak silk moth*                                                                           

  Citropins\                              GLFDVIKKVASVIGGL\                                         60 human cancer cell lines (human tumor line testing program of the US National Cancer Institute) ([@bib0965]); human histiocytic lymphoma cell line ([@bib0985])
  *Australian blue mountains tree frog*   (Citropin 1.1)                                            

  Epinicidin-1\                           GFIFHIIKGLFHAGKMIHGLV                                     Human lung carcinoma, cervix adenocarcinoma, hepatocellular carcinoma, fibrosarcoma, histiocytic lymphoma cells ([@bib1010])
  *Fish*                                                                                            

  Gaegurin-6/-5\                          FLPLLAGLAANFLPTIICKISYKC                                  Human lung, prostate, liver, kidney and breast cancer cell lines ([@bib0980])
  *Korean wrinkled frog*                                                                            

  LL-37\                                  LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES                     Jurkat human T leukemia cells, HeLa cells ([@bib1015])
  *Homo sapiens*                                                                                    

  Magainins\                              GIGKFLHSAKKFGKAFVGEIMNS\                                  Hematopoietic cell lines ([@bib0150]), Ehrlich ascites tumor cells, human adenocarcinoma ([@bib0035]), bladder cancer line ([@bib0990]), histiocytic lymphoma cell line ([@bib0985])
  *African clawed frog*\                  (Magainin 2)\                                             
  \                                       GIGKFLKKAKKFGKAFVKILKK                                    
  Pexiganan (MSI-78)                                                                                

  Melittin\                               GIGAVLKVLTTGLPALISWIKRKRQQ                                Human hepatocellular carcinoma ([@bib0835]); osteosarcoma ([@bib0960]); leukemic cells ([@bib1025]); prostate and ovarian ([@bib0290]), neuroblastoma cancer cells ([@bib0970])
  *Honey bee venom*                                                                                 

  NK-2\                                   KILRGVCKKIMRTFLRRISKDILTGKK\                              Human lymphocytes and seven human cancer cell lines ([@bib0680]); human neuroblastoma cancer cells ([@bib0970])\
  *Porcine leukocytes*\                   KILRGVSKKIMRTFLRRISKDILTGKK                               Human prostate carcinoma cells ([@bib1020])
  NKCS and derivatives                                                                              

  Pep27\                                  MRKEFHNVLSSGQLLADKRPARDYNRK                               Leukemia cell lines ([@bib0995])
  *Strep. pneumonia*                                                                                

  Polybia-MPI\                            IDWKKLLDAAKQIL                                            Human bladder cancer and prostate cancer cell line ([@bib1045])
  *P. paulista*                                                                                     

  Temporin A\                             FLPLIGRVLSGIL                                             Human histiocytic lymphoma cell line ([@bib0985])
  *Frog Rana temporaria*                                                                            

  β-sheet                                                                                           

  Buforin II\                             TRSSRAGLQFPVGRVHRLLRK                                     62 cell lines ([@bib1000]); human histiocytic lymphoma cell line ([@bib0985])
  *Bufo bufo gargarizans*                                                                           

  Human α-defensins\                      ACYCRIPACIAGERRYGTCIYQGRLWAFCC\                           Human lung adenocarcinoma ([@bib0890])\
  *Homo sapiens*\                         (HNP1)\                                                   HeLa, glioma, kidney cancer, lung cancer, myeloma ([@bib0320])
  Defensins                               Diverse sequences                                         

  Gomesin\                                ECRRLCYKQRCVTYCRGR                                        Breast and colon adenocarcinoma, HeLa ([@bib0655])
  *A. gomesiana*                                                                                    

  Lactoferricin B\                        FKCRRWQWRMKKLGAPSITCVRRAF                                 Neuroblastoma ([@bib0195]), melanoma, mammary carcinoma, colorectal adenocarcinoma ([@bib0975])
  *Bovine*                                                                                          

  Protegrin-1\                            RGGRLCYCRRRFCVCVGR                                        Human histiocytic lymphoma cell line ([@bib0985])
  *porcine*                                                                                         

  Tachyplesin I\                          KWCFRVCYRGICYRRCR                                         Human gastric adenocarcinoma ([@bib1035]); human hepatocarcinoma cells ([@bib1005]);
  *Southeast Asian horseshoe crab*                                                                  

  Others                                                                                            

  PR-39\                                  *RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP*                 Human hepatocellular carcinoma cells ([@bib0535])
  *Porcine small intestine*                                                                         

  Alloferon-1/-2\                         *HGVSGHGOHGVHG/GVSGHGVHG*                                 Mice (IFN-production) ([@bib0135])
  *Insects*                                                                                         

  Dolastatin 10\                          Dov-Val-Dil-Dap-Doe[b](#tblfn0010){ref-type="table-fn"}   Murine PS leukemia cells ([@bib0590])
  *D. auricularia*                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For a complete list of anticancer peptides check <http://aps.unmc.edu/AP/database/antiC.php>.

Dolavaline (Dov), dolaisoleuine (Dil), dola-proine (Dap), dolaphenine (Doe).

###### 

*In vivo* studies of anticancer peptides and proposed mode of action.

  Peptide[a](#tblfn0015){ref-type="table-fn"}   Mode of action       Type of tumor
  --------------------------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  α-Helical                                                          
  Magainin and analogues                        Lytic                Murine ascites tumors ([@bib0035]); melanoma xenograft in nude mice ([@bib0755])
  Melittin/avidin-conjugate                     Lytic                Melanoma in mice ([@bib0290])
  Polybia-MPI/MPI-1                             Necrosis             Sarcoma xenograft tumors in mice ([@bib0920])
                                                                     
  β-sheet                                                            
  Human α-defensins                             Apoptosis            Human lung adenocarcinoma xenograft in nude mice ([@bib0890])
  Gomesin                                       Necrosis             Murine melanoma ([@bib0660])
  Lactoferricin B                               Necrosis/Apoptosis   Fibrosarcoma, melanoma, colon carcinoma ([@bib0200]); Xenografting of SH-SY-5Y cells in nude rats ([@bib0195]); inhibition of metastasis of melanoma and lymphoma in mice ([@bib0905])
  RGD-tachyplesin                               Apoptosis            Melanoma mice ([@bib0130])
                                                                     
  Others                                                             
  Dolastatin 10                                 Anti-proliferative   Indolent lymphoma, Waldenstrom\'s macroglobulinemia and chronic lymphocytic leukemia ([@bib0745])
                                                                     
  Synthetic                                                          
  \[[d]{.smallcaps}\]-K~6~L~9~                  Necrosis             Breast cancer in SCID/NCr mice ([@bib0565])
  \[[d]{.smallcaps}\]-H~6~L~9~                  Lytic                22RV1 prostate cancer in mice ([@bib0430])

Source and amino acid composition of peptides are listed in [Table 1](#tbl0005){ref-type="table"}.
